A Retrospective Real-World Cohort Study

NCT07781371 · Not yet recruiting

Last updated 2026-09-22

This study looked at the medical records of people with obesity, type 2 diabetes, prediabetes, heart disease, high cholesterol, liver disease, or kidney disease to track how common these conditions were over time.

Status Not yet recruiting Approved but enrollment has not started.

Type Observational

Participants 100,000 people Planned (estimated).

Who can join Ages 12+ · all sexes

Timeline Started 2026-08 · est. completion 2026-11

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT07781371 ↗

Description as written by the study sponsor.

The primary objectives are to determine the prevalence and overlap of major cardiometabolic diseases, identify multimorbidity clusters, and characterize demographic, clinical, laboratory, and treatment patterns across the cohort and relevant subgroups. This study is based on anonymized electronic health record (EHR) data and spanning January 2022 to December 2025. EHR will be extracted from participants of Acibadem hospital network in Turkey. Participants received routine clinical care according to physician discretion. Index date will be defined by the first diagnosis of cardiometabolic conditions. Follow-up period will include at least one year of to allow description of long-term outcomes. It will extend until the end of study, last recorded encounter, or death.

Treatments tested

No treatment given Other

No treatment given

Main thing measured	Index and yearly prevalence of major cardiometabolic diseases (percentage)
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity, Type 2 Diabetes (T2D), Prediabetes, Cardiovascular Disease (CVD), Dyslipidemia, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Chronic Kidney Disease (CKD)
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07781371 ↗